BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Mar 12, 2012
 |  BioCentury  |  Strategy

Greasing the public-private interface

How partners Bristol-Myers, Duke expect to speed up drug development

Bristol-Myers Squibb Co. and Duke University think their new partnership could be a model for other pharmas and universities to help speed all stages of drug development from preclinical research to post-marketing community outreach.

BMS and the Duke Translational Medicine Institute (DTMI) have formed a joint steering committee that includes scientists and operating managers of divisions like clinical operations and pharmacovigilance who will aim to find common areas of interest that could provide opportunities for collaboration.

The partners also have agreed to put in place a series of master service agreements they think will make it easier for their researchers to collaborate.

"We are still very much focused on individual projects. What we think works best is scientist-scientist interactions on specific topics," said Brian Daniels, SVP of global development and medical affairs at BMS.

Each master service agreement will cover a broad topic, such as clinical trials or community research, and will cover most of the legal terms that are often the sticking points of negotiations that delay the start of research projects. Once the agreements are in place, researchers from each side will be able to start up new projects by...

Read the full 947 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >